{"id":"NCT00744055","sponsor":"Yale University","briefTitle":"Prazosin for Treatment of Patients With Alcohol Dependence (AD) and Post Traumatic Stress Disorder (PTSD).","officialTitle":"The Use of Prazosin for Treatment of Patients With Alcohol Dependence (AD) and Post Traumatic Stress Disorder (PTSD).","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-01","primaryCompletion":"2014-10","completion":"2014-10","firstPosted":"2008-08-29","resultsPosted":"2016-01-18","lastUpdate":"2020-03-19"},"enrollment":96,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Alcohol Dependence","Stress Disorders, Post-Traumatic"],"interventions":[{"type":"DRUG","name":"Prazosin","otherNames":["Minipress"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Prazosin","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"Prazosin is an alpha-1 adrenergic receptor antagonist that has been used successfully in the treatment of trauma nightmares and sleep disturbance in combat veterans with PTSD, and alcohol dependence.\n\nThe objective of this study is to evaluate the efficacy of prazosin (16mg) versus placebo in reducing alcohol consumption and decreasing symptoms of PTSD in patients with comorbid AD and PTSD.","primaryOutcome":{"measure":"Number of Drinking Days","timeFrame":"12 weeks","effectByArm":[{"arm":"Prazosin","deltaMin":11.04,"sd":18.86},{"arm":"Placebo","deltaMin":9.21,"sd":16.64}],"pValues":[]},"eligibility":{"minAge":"21 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":["29461925"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":50},"commonTop":["Alcohol Relapse","Falling","Homocidal Ideation","Partial thrombus","Chest Pain"]}}